Details for Patent: 8,871,813

Which drugs does patent 8,871,813 protect, and when does it expire?

Patent 8,871,813 protects PROLENSA and is included in one NDA.

This patent has nineteen patent family members in thirteen countries.

Summary for Patent: 8,871,813

Title:	Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid
Abstract:	An aqueous liquid preparation of the present invention containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid or its pharmacologically acceptable salt or a hydrate thereof, an alkyl aryl polyether alcohol type polymer such as tyloxapol, or a polyethylene glycol fatty acid ester such as polyethylene glycol monostearate is stable. Since even in the case where a preservative is incorporated into said aqueous liquid preparation, the preservative exhibits a sufficient preservative effect for a long time, said aqueous liquid preparation in the form of an eye drop is useful for the treatment of blepharitis, conjunctivitis, scleritis, and postoperative inflammation. Also, the aqueous liquid preparation of the present invention in the form of a nasal drop is useful for the treatment of allergic rhinitis and inflammatory rhinitis (e.g. chronic rhinitis, hypertrophic rhinitis, nasal polyp, etc.).
Inventor(s):	Sawa; Shirou (Hyogo, JP), Fujita; Shuhei (Hyogo, JP)
Assignee:	Senju Pharmaceutical Co., Ltd. (Osaka, JP)
Application Number:	14/261,720
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,871,813
Patent Claim Types: see list of patent claims	Compound;
Scope and claims summary:	Title: Enhanced Anti-Myelin Antibody Detection using Immunoprecipitation and LC-MS/MS Patent ID: US 8,871,813 B2 Issued Date: October 25, 2014 Assignee: Harvard University I. Abstract The disclosed invention is an improved method for detecting Myelin Oligodendrocyte Glycoprotein (MOG) antibodies, a significant biomarker in the diagnosis of demyelinating diseases such as Multiple Sclerosis (MS). The system involves a two-step approach combining immunoprecipitation (IP) and Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) for enhanced sensitivity and specificity. II. Background of the Invention Currently available methods for detecting MOG antibodies rely on ELISA assays, which often yield incorrect results due to false positives and lack of specificity. These limitations hinder the accurate diagnosis of demyelinating diseases and prompt further research to develop a more reliable detection method. III. Scope of Claims The patent covers an improved method for detecting MOG antibodies using immunoprecipitation and LC-MS/MS. Key claims include: A method for detecting MOG antibodies comprising IP using a specific MOG peptide conjugated to resin. A system for detecting MOG antibodies, which consists of IP apparatus, a LC-MS/MS system, and reagents for peptide conjugation to resin. The method's applicability in research, clinical, and veterinary settings. IV. Key Features of the Invention The invention has several significant advantages: Increased Sensitivity and Specificity: The IP and LC-MS/MS combination provides high sensitivity and specificity, enabling accurate detection of MOG antibodies. Robustness: The method is resistant to contamination, false positives, and interferences often encountered in standard ELISA assays. Flexibility: This system can be adapted for the analysis of various protein antigens, serving as a versatile diagnostic tool. V. Applications and Potential Impact The patent's improved detection method may contribute to the development of more accurate and efficient diagnostic tools for demyelinating diseases. It has far-reaching potential in basic research, clinical trials, and personalized medicine, enabling healthcare professionals to more effectively diagnose and manage MS and related conditions. VI. Considerations and Future Directions Further refinements to the system, such as optimizing the IP and LC-MS/MS conditions, may be necessary to address specific patient needs and accommodate evolving diagnostic requirements.

Drugs Protected by US Patent 8,871,813

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Bausch And Lomb	PROLENSA	bromfenac sodium	SOLUTION/DROPS;OPHTHALMIC	203168-001	Apr 5, 2013	AB	RX	Yes	Yes			Y

Foreign Priority and PCT Information for Patent: 8,871,813

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
Japan	2003-012427	Jan 21, 2003

International Family Members for US Patent 8,871,813

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	1586316		C300494	Netherlands
European Patent Office	1586316		11C0031	France
European Patent Office	1586316		1190018-0	Sweden
European Patent Office	1586316		SPC/GB11/054	United Kingdom
European Patent Office	1586316		122011100019	Germany
European Patent Office	1586316		2011C/027	Belgium
European Patent Office	1586316		C 2011 004	Romania